Insight Molecular Diagnostics (IMDX) EBITDA Margin (2020 - 2026)

Insight Molecular Diagnostics has disclosed EBITDA Margin across 7 years of filings, most recently posting 13790.62% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 13790.62%, down 1347262.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 418.73% (down 15146.0% YoY), and the FY2025 annual result was 260.1%, up 41715.0% from the prior year.
• EBITDA Margin came in at 13790.62% for Q1 2026 at Insight Molecular Diagnostics, down from 1505.0% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 1969.7% in Q1 2023 to a low of 13790.62% in Q1 2026.
• The 5-year median for EBITDA Margin is 1900.0% (2025), against an average of 3176.85%.
• Across the five-year window, EBITDA Margin jumped 750294 bps in 2025 and sank 1347262 bps in 2026, its largest moves.
• Insight Molecular Diagnostics' EBITDA Margin stood at 4251.09% in 2022, then decreased by 21 bps to 5152.55% in 2023, then jumped by 119 bps to 987.55% in 2024, then surged by 52 bps to 1505.0% in 2025, then tumbled by 1016 bps to 13790.62% in 2026.
• The last three EBITDA Margin figures came in at 13790.62% (Q1 2026), 1505.0% (Q4 2025), and 4249.23% (Q3 2025), per Business Quant data.